December 23, 2021
2 min watch
Save
VIDEO: Predicting anemia response to JAK inhibitors among patients with myelofibrosis
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Aaron T. Gerds, MD, MS, speaks with Healio about predictive biomarkers of week 24 transfusion independence among patients with myelofibrosis.
The study was presented at ASH Annual Meeting and Exposition and explored ferritin as a biomarker to predict which patients would and would not experience anemia benefit when treated with Janus kinase (JAK) inhibitors.
Specifically, the researchers compared momelotinib with ruxolitinib (Opzelura, Incyte), according to Gerds, assistant professor of medicine at Cleveland Clinic Taussig Cancer Institute and medical director of Case Comprehensive Cancer Center.
Reference
- Oh ST, et al. Abstract 3638. Presented at: ASH Annual Meeting & Exposition; Dec. 11-14, 2021; Atlanta.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interview
Disclosures:
Gerds reports consulting for AbbVie, Bristol Myers Squibb, Constellation Pharmaceuticals, Novartis, PharmaEssentia and Sierra Oncology; and providing research support for Accurate Pharmaceuticals, Constellation Pharmaceuticals, CTI BioPharma, Imago BioSciences, Incyte Corporation and Kratos Pharmaceuticals.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.